190 related articles for article (PubMed ID: 29883661)
1. Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.
McConnell AM; Mito JK; Ablain J; Dang M; Formichella L; Fisher DE; Zon LI
Dev Biol; 2019 May; 449(2):107-114. PubMed ID: 29883661
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.
Dovey M; White RM; Zon LI
Zebrafish; 2009 Dec; 6(4):397-404. PubMed ID: 19954345
[TBL] [Abstract][Full Text] [Related]
3. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation.
Kaufman CK; Mosimann C; Fan ZP; Yang S; Thomas AJ; Ablain J; Tan JL; Fogley RD; van Rooijen E; Hagedorn EJ; Ciarlo C; White RM; Matos DA; Puller AC; Santoriello C; Liao EC; Young RA; Zon LI
Science; 2016 Jan; 351(6272):aad2197. PubMed ID: 26823433
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M
Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
7. NRAS
Banik I; Cheng PF; Dooley CM; Travnickova J; Merteroglu M; Dummer R; Patton EE; Busch-Nentwich EM; Levesque MP
Pigment Cell Melanoma Res; 2021 Mar; 34(2):150-162. PubMed ID: 32910840
[TBL] [Abstract][Full Text] [Related]
8. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
11. DHODH modulates transcriptional elongation in the neural crest and melanoma.
White RM; Cech J; Ratanasirintrawoot S; Lin CY; Rahl PB; Burke CJ; Langdon E; Tomlinson ML; Mosher J; Kaufman C; Chen F; Long HK; Kramer M; Datta S; Neuberg D; Granter S; Young RA; Morrison S; Wheeler GN; Zon LI
Nature; 2011 Mar; 471(7339):518-22. PubMed ID: 21430780
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
13. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
14. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
Zingg D; Debbache J; Peña-Hernández R; Antunes AT; Schaefer SM; Cheng PF; Zimmerli D; Haeusel J; Calçada RR; Tuncer E; Zhang Y; Bossart R; Wong KK; Basler K; Dummer R; Santoro R; Levesque MP; Sommer L
Cancer Cell; 2018 Jul; 34(1):69-84.e14. PubMed ID: 30008323
[TBL] [Abstract][Full Text] [Related]
15. Nucleotide stress responses in neural crest cell fate and melanoma.
Sporrij A; Zon LI
Cell Cycle; 2021 Aug; 20(15):1455-1467. PubMed ID: 34281491
[TBL] [Abstract][Full Text] [Related]
16. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish.
Santoriello C; Gennaro E; Anelli V; Distel M; Kelly A; Köster RW; Hurlstone A; Mione M
PLoS One; 2010 Dec; 5(12):e15170. PubMed ID: 21170325
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporal expression of NRAS and occurrence of giant congenital melanocytic nevi.
Aimaier R; Chung M; Zhu H; Yu Q
Exp Dermatol; 2022 Apr; 31(4):582-585. PubMed ID: 35020224
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
19. Loss of prdm1a accelerates melanoma onset and progression.
Iwanaga R; Truong BT; Hsu JY; Lambert KA; Vyas R; Orlicky D; Shellman YG; Tan AC; Ceol C; Artinger KB
Mol Carcinog; 2020 Sep; 59(9):1052-1063. PubMed ID: 32562448
[TBL] [Abstract][Full Text] [Related]
20. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
